Developing next generation medicines
that will lead the fight against cancer & inflammation
- Tenalisib- a Phase 2 study in metastatic TNBC patients, post-adjuvant in progress.
- RP12146 – a Phase 1 B expansion study in mCRPC is in progress.
The Rhizen Journey!
Our journey to be a leading biopharmaceutical company developing differentiated products through cutting-edge science and strategic partnerships started in 2008.
Novel programs targeting multiple hallmarks of cancer & inflammation
Assessing the safety and efficacy of our novel pipeline
Accumulated from dedicated research efforts for the last 12 years
We Are All In To Make It Possible
OUR PARTNERING STRATEGY
Flexible Global and Regional Approach
Progress in-house assets through clinical POC/Phase II and out-license to global partners for registration and commercialization across major markets
Explore co-development opportunities with assets that complement Rhizen programs